Clinical trials: Amlodipine
Hypertension
A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan
- Trial name
- NCT01518998
- Where
- South Korea
- Volunteers
- 420 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension With Hyperlipidemia
Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia
To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia
- Trial name
- NCT03536598
- Testing
- Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg, Amlodipine 10 mg + Valsartan 160 mg, Valsartan 160 mg + Rosuvastatin 20 mg
- Volunteers
- 203 people
- Sponsor
- HK inno.N Corporation
Hypertension
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
To evaluate the blood pressure lowering effect and safety of aliskiren 150 mg used in combination with amlodipine 5 mg in patients with essential hypertension not adequately responsive to amlodipine 5 mg.
- Trial name
- NCT00219076
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 504 people
- Sponsor
- Novartis
Hypertension With Hyperlipidemia
Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia
A Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive Patients with Hyperlipidemia
- Trial name
- NCT03566316
- Testing
- Telmisartan/Amlodipine, Rosuvastatin, Telmisartan
- Where
- South Korea
- Volunteers
- 134 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Hypertension, Left Ventricular Hypertrophy
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH.
- Trial name
- NCT00139555
- Testing
- amlodipine/benazepril
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Novartis
Essential Hypertension
Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
An efficacy and safety study of hydrochlorothiazide (+) losartan potassium compared to amlodipine at week 12 in Korean patients with essential hypertension
- Trial name
- NCT00157963
- Testing
- MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks
- Volunteers
- 174 people
- Sponsor
- Organon and Co
Metabolic Syndrome, Hypertension
Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome
The purpose of this study is to study the effect of two doses of olmesartan medoxomil and amlodipine on vascular markers in hypertensive patients with metabolic syndrome.
- Trial name
- VAMOS (NCT00891267)
- Testing
- Olmesartan medoxomil tablets low dose, Olmesartan medoxomil tablets high dose, Amlodipine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Essential Hypertension
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
CS-8635 combines three widely prescribed antihypertensive medications, olmesartan medoxomil(OM), amlodipine (AML), and hydrochlorothiazide (HCTZ), to lower blood pressure.
- Trial name
- NCT01838850
- Where
- 39 sites in South Korea
- Volunteers
- 344 people
- Sponsor
- Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company
Hypertension; Hypertrophy, Left Ventricular
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
This study will evaluate the safety and efficacy of amlodipine plus valsartan in patients with hypertension and left ventricular hypertrophy
- Trial name
- NCT00446563
- Testing
- Valsartan, Amlodipine, Hydrochlorothiazide
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Novartis
Angina
Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine
The study will be a multi-national, double-blind, randomized, placebo-controlled, parallel group study to evaluate the effectiveness of ranolazine (1000 mg twice daily) in approximately 500 patients with chronic angina who remain…
- Trial name
- NCT00091429
- Testing
- Ranolazine
- Volunteers
- 500 people
- Sponsor
- Gilead Sciences
Hypertension
Telmisartan 80mg Non-responder Trial
If a patient cannot have his or her blood pressure controlled with telmisartan 80 mg, an antihypertensive drug from different class should be started concomitantly.
- Trial name
- NCT01222520
- Testing
- Telmisartan and amlodipine, Telmisartan
- Where
- 4 sites in Japan
- Volunteers
- 174 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)
The primary objective of this study was test non-inferiority of telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg in comparison to amlodipine 10 mg + HCTZ 12.5 mg in reducing ambulatory systolic blood pressure (SBP) in the…
- Trial name
- NCT00240474
- Testing
- Telmisartan 80 mg + hydrochlorothiazide 12.5 mg, Amlodipine 10 mg + hydrochlorothiazide 12.5 mg
- Where
- 73 sites in Belgium, Denmark and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Hyperlipidemia
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
The purpose of the study is to measure the effect of the amlodipine/atorvastatin combination pill in reducing both elevated blood pressure and cholesterol levels to levels suggested by guidelines
- Trial name
- GEMINI-AALA (NCT00143234)
- Testing
- Amlodipine/atorvastatin single pill
- Where
- 118 sites in Argentina, Australia and 25 more
- Volunteers
- 1,825 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.
- Trial name
- KARDIA-2 (NCT05103332)
- Testing
- Indapamide, Amlodipine, Olmesartan
- Where
- 110 sites in United States, Canada and 6 more
- Volunteers
- 663 people
- Sponsor
- Alnylam Pharmaceuticals
Hypertension, Hyperlipidemia
Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.
To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.
- Trial name
- JEWEL II (NCT00174304)
- Testing
- Amlodipine/atorvastatin single pill
- Where
- 102 sites in Austria, Belgium and 9 more
- Volunteers
- 1,120 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine)
This study identify prescription patterns of Lodient Tab and evaluate the changes of the hypertension symptoms (BP pressure) who are first prescribed and taking Lodient Tab.
- Trial name
- NCT06214832
- Where
- South Korea
- Volunteers
- 4,000 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Arterial Hypertension
The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension
The use of TRIple fixed-dose COmbination in the treatment of arteriaL hypertension: opportunity for effective BP control with cOmbined antihypertensive therapy.
- Trial name
- TRICOLOR (NCT03722524)
- Testing
- amlodipine / indapamide / perindopril arginine FDC
- Where
- 51 sites in Russia
- Volunteers
- 1,247 people
- Sponsor
- Servier Russia
Hypertension
Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)
To evaluate Drug-drug interaction
- Trial name
- NCT02152969
- Testing
- Telmisartan, Amlodipine, Chlorthalidone
- Where
- South Korea
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Hypertension
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
- Trial name
- NCT00649389
- Testing
- Olmesartan medoxomil, Amlodipine, Hydrochlorothiazide
- Where
- 232 sites in United States, Puerto Rico
- Volunteers
- 2,500 people
- Sponsor
- Daiichi Sankyo
Hypertension
Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension
This study will evaluate the efficacy of valsartan/hydrochlorothiazide versus amlodipine and hydrochlorothiazide in patients with Stage 2 hypertension using 24-hr ambulatory blood pressure monitoring (ABPM)
- Trial name
- NCT00425997
- Testing
- Valsartan/HCTZ, amlodipine, HCTZ
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Novartis